Neuphoria Therapeutics Inc (NEUP)

$4.61 +0.21 (4.77%)
Market Cap 24.64M
Revenue (ttm) 15.65M
Net Income (ttm) -370,000.00
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -2.36%
Debt to Equity Ratio 0.00
Volume 187,100
Avg Vol 49,432
Day's Range N/A - N/A
Shares Out 5.39M
Stochastic %K 55%
Beta 0.50
Analysts Sell
Price Target $9.77

Company Profile

Neuphoria Therapeutics Inc., a clinical stage biopharmaceutical company, discovers and develops novel allosteric ion channel modulators for the treatment of central nervous system disorders in Australia. Its lead product candidate includes BNC210, a selective negative allosteric modulator of the a7 for the treatment of social anxiety disorder; and is phase 2b to treat post-traumatic stress disorder. The company also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial...

Industry: Biotechnology
Sector: Healthcare
Phone: 781 439 5551
Address:
100 Summit Drive, Burlington, United States
skyrockets_Inc
skyrockets_Inc Mar. 19 at 4:44 PM
$NEUP Trial update for Alzheimer's Phase Two trial w/ Merck. Recruiting is complete as of 3/12/2026, 24 week treatment period with some markers checked at 12 weeks. Primary completion with N=350 patients 12/2026. Trial started in 2024 so likely have lots of patients who have already complete and/or are past the 12 week mark. If company is able to see that pre-liminary data they may already know if it looks good or not and hence may want to buy drug outright from Neuphoria. Worth a lot of $$$ if so!
0 · Reply
skyrockets_Inc
skyrockets_Inc Mar. 19 at 4:17 PM
$NEUP Call me crazy but I just did the math and after purchasing more and more shares over the past few weeks I am now the proud owner of 1.3% of the entire company. I believe in a positive outcome here and one that HOPEFULLY comes before the end of the month. LFG!
0 · Reply
skyrockets_Inc
skyrockets_Inc Mar. 18 at 6:42 PM
$NEUP Going to be crickets here until news drops. Good news is that they had over a 'dozen competing indications of interest' in early Dec . We are now 3.5 months from that point so one has to believe a resolution occurs in the next 2 weeks (i.e. by end of Q1). Outcomes by likelihood: 1). RM w/ CVRs for existing assets --> -30% downside risk (low likelihood) for 100%+ potential upside ($3/share - $10/share) 2). Asset sales w/ special dividend and then RM the remaining shell. --> 100 - 200%+ upside ($10+/share) 3). Straight buyout --> 200%+ upside (likely in $12-$15/share range) 4). No deal reached, continue business as usual and collect milestone payments from Merck deal (low likelihood)
0 · Reply
isu2b3vrysus
isu2b3vrysus Mar. 17 at 1:16 PM
$NEUP thoughts on when the announcement will drop?
1 · Reply
hbkstockislife
hbkstockislife Mar. 16 at 2:05 PM
$NEUP CEO will milk it till he can ..it’s like free money to him ..only employee and can do whatever he feels like ..12 offers and it’s been 4 months ..
1 · Reply
hbkstockislife
hbkstockislife Mar. 16 at 12:29 PM
$NEUP why will the CEO be in a hurry when it’s part time for him snd a fat ass check of 32k a month ..Drag it till Dec ..exhaust the cash mofo and then will then do something ..WHY EVEN appoint him for 12 months ..2-3 months wa fine
1 · Reply
skyrockets_Inc
skyrockets_Inc Mar. 13 at 6:40 PM
$NEUP New find that I had missed previously... On Dec 26, 2025 (after the Annual meeting), Lynx update their previous offer to buy the company outright for 4.75/share. The new offer stated that they now want to buy 'certain assets' instead, likely BNC210 based on their comments in previous filings 'Despite the outcome of the trial, our confidence in the assets remains strong.' This matters because we already know the Merck drug has value. BNC210 was the wild card because it had failed a Phase 3 trial in SAD, but may still have benefit in PTSD and other conditions. Lynx being interested in purchasing this asset gives me confidence there is value in this asset as well.
0 · Reply
skyrockets_Inc
skyrockets_Inc Mar. 13 at 4:00 PM
$NEUP Given the timeline from PR in early Dec of having 'over a dozen of competing interests, several with NDAs' I think it's a matter of days/weeks before we get the news. I really think they will announce something before end of Q1, but this Monday could be very likely. We shall see. Load up while you still can!
0 · Reply
skyrockets_Inc
skyrockets_Inc Mar. 12 at 7:14 PM
$CYCN who's going to win the race first?? My $NEUP announcing their deal and me adding 25k more shares to CYCN after said announcement , or @Mr_Pithy settlement check and him adding? the race is on to see who is first!
1 · Reply
skyrockets_Inc
skyrockets_Inc Mar. 11 at 5:23 PM
$NEUP AI agrees w/ my assessment below. RM most likely but asset sale / buyout could fetch a decent amount of money, especially if Merck elects to buy out MK-1167 outright.
1 · Reply
Latest News on NEUP
Leading Proxy Advisory Firm ISS Recommends that Shareholders Vote the WHITE Proxy Card FOR Both of Neuphoria's Director Nominees

Dec 8, 2025, 8:00 AM EST - 3 months ago

Leading Proxy Advisory Firm ISS Recommends that Shareholders Vote the WHITE Proxy Card FOR Both of Neuphoria's Director Nominees

Neuphoria Responds to Lynx1's Revised Indication of Interest at a Reduced Price and Premium

Dec 4, 2025, 8:00 AM EST - 3 months ago

Neuphoria Responds to Lynx1's Revised Indication of Interest at a Reduced Price and Premium

Neuphoria Provides Facts, Exposes False Narratives in Response to Lynx1 Fictions

Dec 1, 2025, 8:00 AM EST - 3 months ago

Neuphoria Provides Facts, Exposes False Narratives in Response to Lynx1 Fictions

Neuphoria Therapeutics Inc. Sends Letter to Stockholders

Nov 24, 2025, 8:00 AM EST - 4 months ago

Neuphoria Therapeutics Inc. Sends Letter to Stockholders

Neuphoria Announces Initiation of Strategic Review to Maximize Stockholder Value

Nov 11, 2025, 7:00 AM EST - 4 months ago

Neuphoria Announces Initiation of Strategic Review to Maximize Stockholder Value

Neuphoria Therapeutics Adopts Limited-Duration Stockholder Rights Plan to Protect Integrity of Process

Oct 27, 2025, 4:29 PM EDT - 5 months ago

Neuphoria Therapeutics Adopts Limited-Duration Stockholder Rights Plan to Protect Integrity of Process

PACCAR Posts Downbeat Earnings, Joins Neuphoria Therapeutics, Citius Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

Oct 21, 2025, 8:16 AM EDT - 5 months ago

PACCAR Posts Downbeat Earnings, Joins Neuphoria Therapeutics, Citius Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

CTXR PCAR

Neuphoria Therapeutics Provides Update on AFFIRM-1 Phase 3 Trial Evaluating BNC210 for the Acute Treatment of Social Anxiety Disorder

Oct 20, 2025, 4:15 PM EDT - 5 months ago

Neuphoria Therapeutics Provides Update on AFFIRM-1 Phase 3 Trial Evaluating BNC210 for the Acute Treatment of Social Anxiety Disorder

Neuphoria Provides Fiscal Year-End 2025 Financial Results and Business Updates

Sep 29, 2025, 4:54 PM EDT - 6 months ago

Neuphoria Provides Fiscal Year-End 2025 Financial Results and Business Updates

Neuphoria Therapeutics Completes Target Enrollment in Phase 3 AFFIRM-1 Trial of BNC-210 in Social Anxiety Disorder (SAD)

Sep 4, 2025, 7:00 AM EDT - 7 months ago

Neuphoria Therapeutics Completes Target Enrollment in Phase 3 AFFIRM-1 Trial of BNC-210 in Social Anxiety Disorder (SAD)

Neuphoria Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 28, 2025, 4:05 PM EDT - 7 months ago

Neuphoria Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Neuphoria to Present at the American Society of Clinical Psychopharmacology (ASCP) 2025 Annual Meeting

May 27, 2025, 4:10 PM EDT - 10 months ago

Neuphoria to Present at the American Society of Clinical Psychopharmacology (ASCP) 2025 Annual Meeting

Neuphoria Provides First Quarter 2025 Business Updates

May 20, 2025, 4:22 PM EDT - 10 months ago

Neuphoria Provides First Quarter 2025 Business Updates

Neuphoria Provides a Review of 2024 and Highlights 2025 Plans

Apr 15, 2025, 8:00 AM EDT - 1 year ago

Neuphoria Provides a Review of 2024 and Highlights 2025 Plans

Neuphoria Therapeutics to Ring the Nasdaq Opening Bell on March 3rd, 2025

Mar 3, 2025, 7:30 AM EST - 1 year ago

Neuphoria Therapeutics to Ring the Nasdaq Opening Bell on March 3rd, 2025

Neuphoria Therapeutics Inc. to Receive $15M Milestone Payment from Merck

Feb 12, 2025, 7:00 AM EST - 1 year ago

Neuphoria Therapeutics Inc. to Receive $15M Milestone Payment from Merck

Neuphoria Completes Re-domiciliation and Successor Listing on Nasdaq

Dec 23, 2024, 4:49 PM EST - 1 year ago

Neuphoria Completes Re-domiciliation and Successor Listing on Nasdaq

skyrockets_Inc
skyrockets_Inc Mar. 19 at 4:44 PM
$NEUP Trial update for Alzheimer's Phase Two trial w/ Merck. Recruiting is complete as of 3/12/2026, 24 week treatment period with some markers checked at 12 weeks. Primary completion with N=350 patients 12/2026. Trial started in 2024 so likely have lots of patients who have already complete and/or are past the 12 week mark. If company is able to see that pre-liminary data they may already know if it looks good or not and hence may want to buy drug outright from Neuphoria. Worth a lot of $$$ if so!
0 · Reply
skyrockets_Inc
skyrockets_Inc Mar. 19 at 4:17 PM
$NEUP Call me crazy but I just did the math and after purchasing more and more shares over the past few weeks I am now the proud owner of 1.3% of the entire company. I believe in a positive outcome here and one that HOPEFULLY comes before the end of the month. LFG!
0 · Reply
skyrockets_Inc
skyrockets_Inc Mar. 18 at 6:42 PM
$NEUP Going to be crickets here until news drops. Good news is that they had over a 'dozen competing indications of interest' in early Dec . We are now 3.5 months from that point so one has to believe a resolution occurs in the next 2 weeks (i.e. by end of Q1). Outcomes by likelihood: 1). RM w/ CVRs for existing assets --> -30% downside risk (low likelihood) for 100%+ potential upside ($3/share - $10/share) 2). Asset sales w/ special dividend and then RM the remaining shell. --> 100 - 200%+ upside ($10+/share) 3). Straight buyout --> 200%+ upside (likely in $12-$15/share range) 4). No deal reached, continue business as usual and collect milestone payments from Merck deal (low likelihood)
0 · Reply
isu2b3vrysus
isu2b3vrysus Mar. 17 at 1:16 PM
$NEUP thoughts on when the announcement will drop?
1 · Reply
hbkstockislife
hbkstockislife Mar. 16 at 2:05 PM
$NEUP CEO will milk it till he can ..it’s like free money to him ..only employee and can do whatever he feels like ..12 offers and it’s been 4 months ..
1 · Reply
hbkstockislife
hbkstockislife Mar. 16 at 12:29 PM
$NEUP why will the CEO be in a hurry when it’s part time for him snd a fat ass check of 32k a month ..Drag it till Dec ..exhaust the cash mofo and then will then do something ..WHY EVEN appoint him for 12 months ..2-3 months wa fine
1 · Reply
skyrockets_Inc
skyrockets_Inc Mar. 13 at 6:40 PM
$NEUP New find that I had missed previously... On Dec 26, 2025 (after the Annual meeting), Lynx update their previous offer to buy the company outright for 4.75/share. The new offer stated that they now want to buy 'certain assets' instead, likely BNC210 based on their comments in previous filings 'Despite the outcome of the trial, our confidence in the assets remains strong.' This matters because we already know the Merck drug has value. BNC210 was the wild card because it had failed a Phase 3 trial in SAD, but may still have benefit in PTSD and other conditions. Lynx being interested in purchasing this asset gives me confidence there is value in this asset as well.
0 · Reply
skyrockets_Inc
skyrockets_Inc Mar. 13 at 4:00 PM
$NEUP Given the timeline from PR in early Dec of having 'over a dozen of competing interests, several with NDAs' I think it's a matter of days/weeks before we get the news. I really think they will announce something before end of Q1, but this Monday could be very likely. We shall see. Load up while you still can!
0 · Reply
skyrockets_Inc
skyrockets_Inc Mar. 12 at 7:14 PM
$CYCN who's going to win the race first?? My $NEUP announcing their deal and me adding 25k more shares to CYCN after said announcement , or @Mr_Pithy settlement check and him adding? the race is on to see who is first!
1 · Reply
skyrockets_Inc
skyrockets_Inc Mar. 11 at 5:23 PM
$NEUP AI agrees w/ my assessment below. RM most likely but asset sale / buyout could fetch a decent amount of money, especially if Merck elects to buy out MK-1167 outright.
1 · Reply
skyrockets_Inc
skyrockets_Inc Mar. 11 at 2:51 PM
$NEUP Entirely possible if they sell the Merck assets
0 · Reply
SpottheBot
SpottheBot Mar. 10 at 9:11 PM
yo whats up $NEUP you getting ready to run to $20 again?
1 · Reply
skyrockets_Inc
skyrockets_Inc Mar. 10 at 7:53 PM
$NEUP That slow 3 month creep up leading up to news.....🔥
0 · Reply
skyrockets_Inc
skyrockets_Inc Mar. 10 at 6:03 PM
$NEUP I expect news to happen in next 2-3 weeks MAX (by end of Q1). All the strategic alternative plays lately have been bangers...expect this to be nothing less. Still has a -30% downside risk if RM deal is TERRIBLE but given they have over 12 competing offers and already rejected a 4.75/share buyout, a bad deal is less likely IMO. $VYNE, $RLYB, $SNSE, all ended amazingly as predicted. This one should be NEXT! LFG!
0 · Reply
hbkstockislife
hbkstockislife Mar. 6 at 8:47 PM
$NEUP who even buys this junk lol
1 · Reply
skyrockets_Inc
skyrockets_Inc Mar. 4 at 7:18 PM
$NEUP Dec 4 PR, never forget (3 months ago): "the Company has already received a substantial number of competing indications of interest, with nearly a dozen that have already advanced to NDAs and separate process letter proposals. " " the Board’s ability to fully independently evaluate these agreements and any strategic alternatives, INCLUDING POTENTIAL OFFERS." NEUP might actually be a better buyout candidate than a RM candidate considering they have very little USD NOLs. Either way, news likely VERY SOON. :)
1 · Reply
SDBiotechInvestor
SDBiotechInvestor Mar. 4 at 5:43 PM
$NEUP - very suspicious volume. I think the news is imminent.
1 · Reply
kshonstocks
kshonstocks Mar. 4 at 3:33 PM
$NEUP hitting scans off this bottom
0 · Reply
skyrockets_Inc
skyrockets_Inc Mar. 3 at 7:20 PM
$NEUP Here are my predicted likely outcomes for the strategic process (in order of likelihood imo): 1). Reverse merger w/ either asset sales or CVRs , or combination of both. This would mimic a similar deal to what $RLYB just did. However, $RLYB had a better cash position so the price movement in this option will depend entirely on how good the terms of the RM are. --> -30% downside risk for a potential 2-3x upside. 2). Buyout. Lynx1 group offered 4.75 for the entire company so there is precedent for it. The BOD rejected this offer because ... "Simply stated, Lynx1’s non-binding proposal does not present an attractive value, and certainly not one that would compel the Board to consider abandoning its ongoing strategic review process – especially given that the Company has already received a substantial number of competing indications of interest, with nearly a dozen that have already advanced to NDAs and separate process letter proposals. " --> 2x minimum, 3-4x possible
0 · Reply
SDBiotechInvestor
SDBiotechInvestor Mar. 2 at 8:45 PM
$NEUP - Went long today after being in $RLYB for several months. Think we will see a similar outcome as Sky mentions below. Lots of ways to win here.
0 · Reply
skyrockets_Inc
skyrockets_Inc Mar. 2 at 4:36 PM
$NEUP Now that $RLYB has exploded I've added to my position here. Still think an outcome on this by end of Q1 (March 31). Strat alts since Nov and had hostile takeover attempt for 4.75/share which got rejected. Several valuable assets still in pipeline with one partnered w/ MERCK. Likely going to be RM here as only 1 employee left. RM w/ CVRS similar to $RLYB likely today. Cash value not as good as RallyBio so downside risk is more, I'd say -30% downside risk for a potential 2-3x upside. LFG!
1 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 27 at 1:46 PM
$NEUP RSI: 69.52, MACD: 0.0717 Vol: 0.16, MA20: 4.14, MA50: 4.03 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply